SeaStar_SM_LogoCard.png
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation
June 07, 2024 08:30 ET | SeaStar Medical Holding Corporation
DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility
May 22, 2024 08:30 ET | SeaStar Medical Holding Corporation
SCD’s ability to improve clinical status of four critically ill pediatric and adult patients across multiple clinical conditions published in Transplantation Direct DENVER, May 22, 2024 (GLOBE...
SeaStar_SM_LogoCard.png
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
April 17, 2024 16:00 ET | SeaStar Medical Holding Corporation
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary...
SeaStar_SM_LogoCard.png
SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference
April 11, 2024 08:30 ET | SeaStar Medical Holding Corporation
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
March 27, 2024 08:30 ET | SeaStar Medical Holding Corporation
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...
Picture1.png
Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
December 27, 2023 08:01 ET | PowerUp Acquisition Corp.
Tarrytown, NY and New York, NY, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Visiox Pharmaceuticals, Inc. (“Visiox” or the “Company”), a commercial-stage biopharmaceutical company, and PowerUp Acquisition...
Logo.png
Lucid Diagnostics Announces Pricing of Initial Public Offering
October 13, 2021 22:15 ET | Lucid Diagnostics Inc.
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:...
PAVMEDLOGONEW15OCT2018.png
PAVmed to Hold Business Update Conference Call on May 17, 2021
May 03, 2021 09:30 ET | PAVmed Inc.
Company conference call and webcast at 4:30 PM EDT NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated,...
PAVMEDLOGONEW15OCT2018.png
PAVmed to Present at the 20th Annual Needham Healthcare Conference
April 08, 2021 09:30 ET | PAVmed Inc.
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today...
PAVMEDLOGONEW15OCT2018.png
PAVmed Announces Proposed Public Offering of Common Stock
February 22, 2021 16:13 ET | PAVmed Inc.
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...